Compare FFBC & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FFBC | ACAD |
|---|---|---|
| Founded | 1863 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.8B |
| IPO Year | 2004 | 2000 |
| Metric | FFBC | ACAD |
|---|---|---|
| Price | $34.49 | $26.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 22 |
| Target Price | ★ $30.71 | $30.55 |
| AVG Volume (30 Days) | 1.0M | ★ 1.8M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.34% | N/A |
| EPS Growth | 10.83 | ★ 69.12 |
| EPS | ★ 0.71 | 0.02 |
| Revenue | N/A | ★ $726,437,000.00 |
| Revenue This Year | $27.67 | $18.80 |
| Revenue Next Year | $4.58 | $11.70 |
| P/E Ratio | ★ $47.90 | $1,320.00 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $23.09 | $19.69 |
| 52 Week High | $35.00 | $28.35 |
| Indicator | FFBC | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 65.20 | 74.40 |
| Support Level | $29.32 | $25.40 |
| Resistance Level | $35.00 | $27.79 |
| Average True Range (ATR) | 0.71 | 0.94 |
| MACD | 0.01 | 0.23 |
| Stochastic Oscillator | 85.30 | 82.17 |
First Financial Bancorp is a mid-sized, regional bank holding company. It engages in the business of commercial banking and other banking and banking-related activities through its subsidiary. The range of banking services provided to individuals and businesses includes commercial lending, real estate lending, and consumer financing. Real estate loans are loans secured by a mortgage lien on the real property of the borrower, which may either be residential property or commercial property. In addition, it offers deposit products that include interest-bearing and non-interest-bearing accounts, time deposits, and cash management services for commercial customers. A full range of trust and wealth management services is also provided through First Financial's Wealth Management line of business.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.